Regeneron Pharmaceuticals, Inc. (REGN) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Regeneron Pharmaceuticals (REGN) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. The real thesis is a fast-growing Dupixent franchise and one of biotech's most productive R&D engines (VelociSuite plus the Regeneron Genetics Center), which together fund a deep pipeline across immunology, oncology, and eye disease. The single biggest risk is biosimilar erosion of the legacy Eylea franchise, where lower-priced copies are entering the U.S. market and pressuring a business that was long a core profit driver.
REGN stock price
As of 2026-11-16, Regeneron Pharmaceuticals, Inc. (REGN) last closed at $952.40, up 35.2% over the past year. Over the past 52 weeks it has traded between $600.66 and $973.36.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Regeneron Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
REGN key stats
At $952.40 on November 16, 2026, Regeneron Pharmaceuticals, Inc. (REGN) has a market cap of $98.5B, a P/E of 21.1 on trailing earnings (13.5 on forward earnings) and a dividend yield of 0.39%. It next reports earnings around January 28, 2027 (estimated).
- Market cap
- $98.5B
- P/E (trailing)
- 21.1
- P/E (forward)
- 13.5
- EPS (trailing 12 months)
- $45.24
- Price to book
- 2.9
- Dividend yield
- 0.39%
- Beta
- 0.09
- Next earnings
- around January 28, 2027 (estimated)
Market cap, P/E and yield are measured at the $952.40 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Regeneron Pharmaceuticals, Inc. (REGN)?
The last two weeks for Regeneron Pharmaceuticals, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- REGN closed at $952.40 on November 16, 2026, up 3.5% over the past five trading days (from $919.96).
- Regeneron Pharmaceuticals, Inc. next reports quarterly results around January 28, 2027 (estimated).
Regeneron Pharmaceuticals, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Regeneron Pharmaceuticals, Inc. (REGN) latest quarter
Regeneron reported revenue of $5.1 billion for Q3 2026, up 36% from a year earlier (Regeneron, Oct 30, 2026).
Source: Regeneron Q3 2026 results, Oct 30, 2026. Full earnings breakdown
What does Regeneron Pharmaceuticals, Inc. (REGN) do?
Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base. Total revenue then stepped up to about $4.29 billion in Q2 2026, up roughly 17% year over year, taking trailing twelve-month revenue to about $15.5 billion and net income to about $4.3 billion.
Regeneron was founded in 1988 by Leonard Schleifer, who remains a central leader, with chief scientific officer George Yancopoulos shaping its science-first culture. The company built its reputation on proprietary VelociSuite antibody-discovery technologies and the Regeneron Genetics Center, an internal engine that turns large-scale human genetics into drug targets. That R&D productivity, rather than acquisitions, has historically driven its growth. In 2025 the board initiated its first quarterly dividend and expanded share repurchases, signaling a more mature capital-return posture alongside heavy ongoing R&D investment. At about $794 per share on October 16, 2026, the company was valued near $82 billion, roughly 20 times trailing and 13 times forward earnings, with Q3 2026 results due October 30, 2026.
What's driving Regeneron Pharmaceuticals, Inc. (REGN)?
Dupixent keeps compounding
Dupixent remains the central growth driver, with global net sales rising about 31% to roughly $4.9 billion in Q1 2026 and label expansions into conditions like COPD and chronic spontaneous urticaria widening the addressable population. Because Regeneron splits economics with Sanofi, growth flows through as rising collaboration revenue. As long as new indications and geographies keep landing, this franchise can offset pressure elsewhere in the portfolio.
A deep, diversified pipeline
Regeneron carries nearly 50 clinical candidates across roughly six therapeutic areas, including hematology-oncology, complement-mediated diseases, and anticoagulation. The company also logged its first gene therapy approval, a move beyond antibodies, and in October 2026 it reported 84-week Phase III efficacy data for its treatment of fibrodysplasia ossificans progressiva (FOP), a rare bone disorder. This breadth means the investment case does not rest on any single readout, though individual trials still carry binary outcomes.
R&D productivity as a moat
The VelociSuite platform and Regeneron Genetics Center give the company an internal discovery engine that has repeatedly produced approved medicines without relying on large acquisitions. Planned R&D investment of roughly $6.6 billion in 2026 reflects management's bet that this engine keeps generating the next franchises. Investors who value durable innovation tend to anchor on this capability rather than any one drug.
Oncology optionality
Libtayo anchors a growing oncology effort, with fianlimab and other programs advancing in late-stage development. On October 16, 2026 the EMA's CHMP recommended EU approval of an updated Libtayo dosing regimen across all of its approved cancer types. Oncology could become a third major pillar alongside immunology and eye disease over time. It is earlier in its revenue contribution, so it represents upside optionality more than a current cash driver.
What are the risks to Regeneron Pharmaceuticals, Inc. (REGN)?
The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.
What is the Regeneron Pharmaceuticals, Inc. (REGN) forecast?
27 analysts publish price targets on REGN, averaging $977.93 as of November 2026, or +2.7% against the $952.40 share price on November 16, 2026. The published targets run from $812.00 to $1175.00, a moderate spread, and the ratings split 19 buy, 9 hold, 0 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full REGN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is REGN a buy or a sell?
We give no verdict on Regeneron Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Dupixent keeps compounding. Dupixent remains the central growth driver, with global net sales rising about 31% to roughly $4.9 billion in Q1 2026 and label expansions into conditions like COPD and chronic spontaneous urticaria widening the addressable population. The most optimistic published target, $1175.00, assumes this works close to its best case.
The case against. The clearest risk is Eylea biosimilar erosion. The most pessimistic target, $812.00, is roughly what REGN is worth if this bites instead.
Read the full bull and bear case on REGN, including what would have to change to break either one. Walnut is not an investment adviser.
Has Regeneron Pharmaceuticals, Inc. (REGN) split its stock?
No. Regeneron Pharmaceuticals, Inc. (REGN) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Regeneron Pharmaceuticals, Inc. (REGN) valued?
Market cap, P/E and dividend yield at today's price are in the REGN key stats above. The business figures below come from Regeneron Pharmaceuticals, Inc.'s reported results as of October 2026 and change when it next reports.
- Total revenue (TTM): ~$15.5 billion
- Q2 2026 total revenue: ~$4.29 billion (up ~17% YoY)
- Q2 2026 EPS vs estimate: ~$14.29 vs ~$10.21
- Net income (TTM): ~$4.3 billion (~28% net margin)
- Dupixent global net sales (Q1 2026): ~$4.9 billion (up ~31%)
- Cash / debt: ~$8.0 billion cash, ~$2.7 billion debt
As of October 2026: Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron has beaten EPS estimates in each of the last four quarters, most sharply in Q2 2026 (about $14.29 against $10.21), and the shares rose about 18% over three months to roughly $794, up about 40% over a year. Consensus for Q3 2026, due October 30, sits near $16.06 of EPS on about $4.54 billion of revenue, and the ~13x forward P/E reflects the market weighing strong Dupixent growth against Eylea biosimilar erosion expected to accelerate around the fourth quarter of 2026.
Which ETFs hold Regeneron Pharmaceuticals, Inc. (REGN)?
What themes does Regeneron Pharmaceuticals, Inc. (REGN) fit?
These are the investment theses REGN naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.
Who competes with Regeneron Pharmaceuticals, Inc. (REGN)?
Large biopharma and immunology rivals
Companies like AbbVie, Amgen, Bristol Myers Squibb, and Sanofi (also Regeneron's Dupixent partner) compete across immunology and inflammation, the therapeutic area where Dupixent operates. These firms have comparable R&D scale and overlapping pipelines in eczema, asthma, and related conditions.
Eylea biosimilar makers
Amgen (Pavblu), Sandoz, and the Alvotech and Teva partnership are bringing lower-priced biosimilar copies of Eylea to the U.S. market. They compete directly on price in retinal disease, the central source of pressure on Regeneron's legacy ophthalmology franchise.
Eye-disease and oncology competitors
Roche and Novartis market rival retinal therapies such as Vabysmo and Beovu, competing with Eylea and Eylea HD. In oncology, Merck, Bristol Myers Squibb, and others field established immunotherapies that Libtayo and Regeneron's pipeline must compete against.
What stocks are similar to Regeneron Pharmaceuticals, Inc. (REGN)?
Other names that sit close to REGN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Regeneron Pharmaceuticals, Inc. (REGN)
There are three common ways to get REGN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (BBH, IBB), which spreads the position across many companies. Or build it into a focused thematic portfolio, so REGN sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where REGN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron today is two stories layered on top of each other: a Dupixent-led immunology franchise that grew global net sales roughly 31% to about $4.9 billion in Q1 2026, and a legacy Eylea eye-disease business now facing direct biosimilar competition. The company is broadening into oncology (Libtayo, fianlimab) and other areas while Eylea HD, a higher-dose formulation, defends share. Q2 2026 then delivered about $4.29 billion of total revenue, up roughly 17%, and an EPS beat (about $14.29 against $10.21), and the shares closed near $794 on October 16, 2026, up about 40% over a year. If you believe the pipeline and Dupixent growth can outrun the Eylea decline, the question becomes sizing and overlap with other healthcare holdings you already own, not timing. The risk is that biosimilar erosion accelerates faster than newer products scale.
More on Regeneron Pharmaceuticals, Inc. (REGN)
Whether REGN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is REGN a buy or a sell?, and where the stock could go from here in the REGN stock forecast.
For income investors, whether REGN pays a dividend and how the payout looks is covered in does REGN pay a dividend? And to weigh REGN against a peer, read the full side-by-side comparisons: REGN vs VRTX and REGN vs GILD.
Wondering how REGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Regeneron Pharmaceuticals, Inc.
Ask Walnut's AI anything about REGN and see how it fits what you own.
FAQ
Is REGN a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is Dupixent growth plus a productive R&D engine and deep pipeline. The bear case is accelerating Eylea biosimilar erosion and franchise concentration. A long-term investor comfortable with biotech volatility weighs those differently than someone needing near-term stability. Consider how REGN fits your overall portfolio and existing healthcare exposure.
What does Regeneron do?
+
Regeneron is a biotechnology company that discovers, develops, and sells medicines. Its largest products are Dupixent for inflammatory diseases such as eczema and asthma (partnered with Sanofi), and Eylea and Eylea HD for retinal eye diseases. It also markets Libtayo in oncology and runs a broad pipeline built on its VelociSuite discovery platform and the Regeneron Genetics Center.
Does REGN pay a dividend?
+
Yes. Regeneron initiated its first quarterly cash dividend in 2025, declaring $0.88 per share, alongside expanded share repurchases. The current annualized rate is about $3.76 per share, a yield of roughly 0.5% at the October 16, 2026 price near $794, so REGN is primarily a growth-oriented holding rather than an income stock. Most of its shareholder return historically came through buybacks and share-price appreciation rather than dividend payments.
What is Regeneron's biggest drug?
+
Dupixent is Regeneron's biggest and fastest-growing franchise. Global net sales reached about $4.9 billion in Q1 2026, up roughly 31% year over year, driven by expanding approvals across eczema, asthma, COPD, and other inflammatory conditions. Because it is developed with Sanofi, Regeneron records its share as Sanofi collaboration revenue rather than direct product sales.
Why is Eylea biosimilar competition a concern for REGN?
+
Eylea was long a core profit driver, so lower-priced biosimilar copies threaten a meaningful revenue stream. Amgen's Pavblu launched in late 2024, and settlements clear paths for Sandoz, Alvotech, and Teva to launch around the fourth quarter of 2026. Management expects erosion to accelerate in the second half of 2026, partly offset by the higher-dose Eylea HD and Dupixent growth.
How can I invest in Regeneron through an ETF?
+
Regeneron is a constituent of many broad healthcare and biotechnology ETFs, including large biotech-focused funds and S&P 500 index funds. Buying such an ETF gives you REGN exposure alongside dozens or hundreds of other companies, which spreads single-stock risk. Check a fund's holdings list to see Regeneron's weight before assuming it is a major position.
What is VelociSuite and why does it matter?
+
VelociSuite is Regeneron's suite of proprietary technologies for discovering and developing antibody-based drugs efficiently. Combined with the Regeneron Genetics Center, which mines large-scale human genetics for drug targets, it has produced multiple approved medicines without relying on big acquisitions. Many investors view this internal R&D productivity as Regeneron's most durable competitive advantage.
How did Regeneron do in its latest quarter?
+
In Q2 2026 Regeneron reported total revenue of about $4.29 billion, up roughly 17% year over year and ahead of expectations, with net income of about $1.3 billion. EPS of about $14.29 beat the roughly $10.21 consensus, the fourth straight quarterly beat. Q3 2026 results are scheduled for October 30, 2026, with consensus near $16.06 per share on about $4.54 billion of revenue.
How has REGN stock performed in 2026?
+
REGN closed at about $793.92 on October 16, 2026, up roughly 2.3% year to date and about 39.5% over one year, within a 52-week range of about $566 to $859. It rose about 17.6% over three months after the Q2 beat, and UBS upgraded the stock on October 15, 2026. Walnut is not an investment adviser, and past performance does not indicate future returns.
Guides that feature REGN
REGN is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Regeneron Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.